Skip to main content
Erschienen in:

09.03.2021 | Original Paper

The cost of chemotherapy administration: a systematic review and meta-analysis

verfasst von: Gursharan K. Sohi, Jordan Levy, Victoria Delibasic, Laura E. Davis, Alyson L. Mahar, Elmira Amirazodi, Craig C. Earle, Julie Hallet, Ahmed Hammad, Rajan Shah, Nicole Mittmann, Natalie G. Coburn

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer treatment is a significant driver of healthcare costs worldwide, however, the economic impact of treating patients with anti-neoplastic agents is poorly elucidated. We conducted a systematic review and meta-analysis to estimate the direct costs associated with administering intravenous chemotherapy in an outpatient setting.

Methods

We systematically searched four databases from 2010 to present and extracted hourly administration costs and the respective components of each estimate. Separate analyses were conducted of Canadian and United States (US) studies, respectively, to address a priori hypotheses regarding heterogeneity amongst estimates. The Drummond checklist was used to assess risk-of-bias. Data were summarized using medians with interquartile ranges and five outliers were identified; costs were presented in 2019 USD.

Results

Forty-four studies were analyzed, including sub-analyses of 19 US and seven Canadian studies. 26/44 studies were of moderate-high quality. When components of administration cost were evaluated, physician costs were reported most frequently (24 studies), followed by lab tests (13) and overhead costs (9). The median estimate (excluding outliers) was $142/hour (IQR = $103–166). The median administration cost in the US was $149/hour (IQR = $118–158), and was $128/hour (IQR = $102–137) in Canada.

Conclusions

There is currently a paucity of literature addressing the costs of chemotherapy administration, and existing studies utilize a patchwork of reporting methodologies which renders direct comparison challenging. Our results demonstrate that the cost of administering chemotherapy is approximately $125–150/hour, globally. This value is dependent upon the region of analysis, inclusiveness of cost subcomponents as well as the methodology used to estimate unit prices, as described here.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Albaba, H., Lim, C., Leighl, N.B.: Economic considerations in the use of novel targeted therapies for lung cancer: review of current literature. Pharmacoeconomics 35, 1195–1209 (2017)PubMedCrossRef Albaba, H., Lim, C., Leighl, N.B.: Economic considerations in the use of novel targeted therapies for lung cancer: review of current literature. Pharmacoeconomics 35, 1195–1209 (2017)PubMedCrossRef
3.
Zurück zum Zitat Nabhan, C., Feinberg, B.A.: Value-based calculators in cancer: current state and challenges. J Oncol Pract 13, 499–506 (2017)PubMedCrossRef Nabhan, C., Feinberg, B.A.: Value-based calculators in cancer: current state and challenges. J Oncol Pract 13, 499–506 (2017)PubMedCrossRef
4.
Zurück zum Zitat Moher, D., Liberati, A., Tetzlaff, J., et al.: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097 (2009)PubMedPubMedCentralCrossRef Moher, D., Liberati, A., Tetzlaff, J., et al.: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097 (2009)PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Drummond, M., et al.: Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford (1997) Drummond, M., et al.: Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford (1997)
10.
Zurück zum Zitat Drummond, M.F., Jefferson, T.O.: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party. BMJ 313, 275–283 (1996)PubMedPubMedCentralCrossRef Drummond, M.F., Jefferson, T.O.: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party. BMJ 313, 275–283 (1996)PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Saxton, A.T., Poenaru, D., Ozgediz, D., et al.: Economic analysis of children’s surgical care in low- and middle-income countries: a systematic review and analysis. PLoS ONE 11, e0165480 (2016)PubMedPubMedCentralCrossRef Saxton, A.T., Poenaru, D., Ozgediz, D., et al.: Economic analysis of children’s surgical care in low- and middle-income countries: a systematic review and analysis. PLoS ONE 11, e0165480 (2016)PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Abbott, D.E., Merkow, R.P., Cantor, S.B., et al.: Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol 19, 3659–3667 (2012)PubMedCrossRef Abbott, D.E., Merkow, R.P., Cantor, S.B., et al.: Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol 19, 3659–3667 (2012)PubMedCrossRef
13.
Zurück zum Zitat Abbott, D.E., Tzeng, C.-W.D., Merkow, R.P., et al.: the cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol 20(Suppl 3), S500-508 (2013)PubMedCrossRef Abbott, D.E., Tzeng, C.-W.D., Merkow, R.P., et al.: the cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol 20(Suppl 3), S500-508 (2013)PubMedCrossRef
14.
Zurück zum Zitat Amdahl, J., Manson, S.C., Isbell, R., et al.: Cost-effectiveness of oazopanib in advanced soft tissue sarcoma in the united kingdom. Sarcoma 2014, 481071 (2014)PubMedPubMedCentralCrossRef Amdahl, J., Manson, S.C., Isbell, R., et al.: Cost-effectiveness of oazopanib in advanced soft tissue sarcoma in the united kingdom. Sarcoma 2014, 481071 (2014)PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Awan, F., Kochuparambil, S.T., Falconer, D.E., et al.: Comparable efficacy and lower cost of PBSC mobilization with Intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 48, 1279–1284 (2013)PubMedCrossRef Awan, F., Kochuparambil, S.T., Falconer, D.E., et al.: Comparable efficacy and lower cost of PBSC mobilization with Intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 48, 1279–1284 (2013)PubMedCrossRef
16.
Zurück zum Zitat Babashov, V., Begen, M.A., Mangel, J., et al.: Economic evaluation of brentuximab vedotin for persistent hodgkin lymphoma. Curr Oncol 24, e6–e14 (2017)PubMedPubMedCentralCrossRef Babashov, V., Begen, M.A., Mangel, J., et al.: Economic evaluation of brentuximab vedotin for persistent hodgkin lymphoma. Curr Oncol 24, e6–e14 (2017)PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Bernard, L.M., Verma, S., Thompson, M.F., et al.: A Canadian economic analysis of U.S. Oncology adjuvant trial 9735. Curr Oncol 18, 67–75 (2011)PubMedPubMedCentralCrossRef Bernard, L.M., Verma, S., Thompson, M.F., et al.: A Canadian economic analysis of U.S. Oncology adjuvant trial 9735. Curr Oncol 18, 67–75 (2011)PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Chen, Q., Ayer, T., Nastoupil, L.J., et al.: Comparing the cost-effectiveness of Rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health 18, 189–197 (2015)PubMedPubMedCentralCrossRef Chen, Q., Ayer, T., Nastoupil, L.J., et al.: Comparing the cost-effectiveness of Rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health 18, 189–197 (2015)PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Dranitsaris, G., Coleman, R., Gradishar, W.: Nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with Metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 119, 717–724 (2010)PubMedCrossRef Dranitsaris, G., Coleman, R., Gradishar, W.: Nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with Metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 119, 717–724 (2010)PubMedCrossRef
20.
Zurück zum Zitat Duong, M., Wright, E., Yin, L., et al.: The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada. Curr Oncol 23, e461–e467 (2016)PubMedPubMedCentralCrossRef Duong, M., Wright, E., Yin, L., et al.: The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada. Curr Oncol 23, e461–e467 (2016)PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Durkee, B.Y., Qian, Y., Pollom, E.L., et al.: Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 34, 902–909 (2016)PubMedCrossRef Durkee, B.Y., Qian, Y., Pollom, E.L., et al.: Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 34, 902–909 (2016)PubMedCrossRef
22.
Zurück zum Zitat Espinosa Bosch, M., Asensi Diez, R., García Agudo, S., et al.: Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report. Farm Hosp 40, 316–327 (2016)PubMed Espinosa Bosch, M., Asensi Diez, R., García Agudo, S., et al.: Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report. Farm Hosp 40, 316–327 (2016)PubMed
23.
Zurück zum Zitat Farolfi, A., Silimbani, P., Gallegati, D., et al.: Resource utilization and cost saving analysis of subcutaneous versus intravenous Trastuzumab in early breast cancer patients. Oncotarget 8, 81343–81349 (2017)PubMedPubMedCentralCrossRef Farolfi, A., Silimbani, P., Gallegati, D., et al.: Resource utilization and cost saving analysis of subcutaneous versus intravenous Trastuzumab in early breast cancer patients. Oncotarget 8, 81343–81349 (2017)PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Flannery, K., Drea, E., Hudspeth, L., et al.: budgetary impact of cabazitaxel use after docetaxel treatment for metastatic castration-resistant prostate cancer. J Manag Care Spec Pharm 23, 416–426 (2017)PubMed Flannery, K., Drea, E., Hudspeth, L., et al.: budgetary impact of cabazitaxel use after docetaxel treatment for metastatic castration-resistant prostate cancer. J Manag Care Spec Pharm 23, 416–426 (2017)PubMed
25.
Zurück zum Zitat Gharaibeh, M., McBride, A., Bootman, J.L., et al.: Economic evaluation for the US of Nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. J Med Econ 20, 345–352 (2017)PubMedCrossRef Gharaibeh, M., McBride, A., Bootman, J.L., et al.: Economic evaluation for the US of Nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. J Med Econ 20, 345–352 (2017)PubMedCrossRef
26.
Zurück zum Zitat Goldstein, D.A., Chen, Q., Ayer, T., et al.: Cost effectiveness analysis of pharmacokinetically-guided 5-Fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 13, 219–225 (2014)PubMedCrossRef Goldstein, D.A., Chen, Q., Ayer, T., et al.: Cost effectiveness analysis of pharmacokinetically-guided 5-Fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 13, 219–225 (2014)PubMedCrossRef
27.
Zurück zum Zitat Goldstein, D.A., Chen, Q., Ayer, T., et al.: First- and second-line Bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 33, 1112–1118 (2015)PubMedPubMedCentralCrossRef Goldstein, D.A., Chen, Q., Ayer, T., et al.: First- and second-line Bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 33, 1112–1118 (2015)PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Goldstein, D.A., Chen, Q., Ayer, T., et al.: Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol 1, 1293–1300 (2015)PubMedCrossRef Goldstein, D.A., Chen, Q., Ayer, T., et al.: Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol 1, 1293–1300 (2015)PubMedCrossRef
29.
Zurück zum Zitat Goulart, B., Ramsey, S.: A trial-based assessment of the cost-utility of Bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14, 836–845 (2011)PubMedCrossRef Goulart, B., Ramsey, S.: A trial-based assessment of the cost-utility of Bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14, 836–845 (2011)PubMedCrossRef
30.
Zurück zum Zitat Haywood, P., de Raad, J., van Gool, K., et al.: Chemotherapy administration: modelling the costs of alternative protocols. Pharmacoeconomics 30, 1173–1186 (2012)PubMedCrossRef Haywood, P., de Raad, J., van Gool, K., et al.: Chemotherapy administration: modelling the costs of alternative protocols. Pharmacoeconomics 30, 1173–1186 (2012)PubMedCrossRef
31.
Zurück zum Zitat He, J., Wen, F., Yin, X., et al.: Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer. Anticancer Drugs 24, 754–758 (2013)PubMedCrossRef He, J., Wen, F., Yin, X., et al.: Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer. Anticancer Drugs 24, 754–758 (2013)PubMedCrossRef
32.
Zurück zum Zitat Hornberger, J., Chien, R., Friedmann, M., et al.: Cost-effectiveness of Rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. Leuk Lymphoma 53, 2371–2377 (2012)PubMedCrossRef Hornberger, J., Chien, R., Friedmann, M., et al.: Cost-effectiveness of Rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. Leuk Lymphoma 53, 2371–2377 (2012)PubMedCrossRef
33.
Zurück zum Zitat Hornberger, J., Hirsch, F.R., Li, Q., et al.: Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial. Lung Cancer 88, 223–230 (2015)PubMedCrossRef Hornberger, J., Hirsch, F.R., Li, Q., et al.: Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial. Lung Cancer 88, 223–230 (2015)PubMedCrossRef
34.
Zurück zum Zitat Howard, D.R., Munir, T., McParland, L., et al.: Clinical effectiveness and cost-effectiveness results from the randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the attenuated dose rituximab with chemotherapy in chronic lymphocytic leukaemia (ARCTIC) trial. Health Technol Assess 21, 1–374 (2017)PubMedPubMedCentralCrossRef Howard, D.R., Munir, T., McParland, L., et al.: Clinical effectiveness and cost-effectiveness results from the randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the attenuated dose rituximab with chemotherapy in chronic lymphocytic leukaemia (ARCTIC) trial. Health Technol Assess 21, 1–374 (2017)PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Hui, L., von Keudell, G., Wang, R., et al.: Cost-effectiveness analysis of consolidation with Brentuximab Vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 123, 3763–3771 (2017)PubMedCrossRef Hui, L., von Keudell, G., Wang, R., et al.: Cost-effectiveness analysis of consolidation with Brentuximab Vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 123, 3763–3771 (2017)PubMedCrossRef
36.
Zurück zum Zitat Joerger, M., Matter-Walstra, K., Früh, M., et al.: Addition of Cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 22, 567–574 (2011)PubMedCrossRef Joerger, M., Matter-Walstra, K., Früh, M., et al.: Addition of Cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 22, 567–574 (2011)PubMedCrossRef
37.
Zurück zum Zitat Kumar, G., Woods, B., Hess, L.M., et al.: Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer 89, 294–300 (2015)PubMedCrossRef Kumar, G., Woods, B., Hess, L.M., et al.: Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer 89, 294–300 (2015)PubMedCrossRef
38.
Zurück zum Zitat Lachaine, J., Mathurin, K., Barakat, S., et al.: Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. Eur J Haematol 95, 218–229 (2015)PubMedCrossRef Lachaine, J., Mathurin, K., Barakat, S., et al.: Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. Eur J Haematol 95, 218–229 (2015)PubMedCrossRef
39.
Zurück zum Zitat Lachaine, J., Mathurin, K., Barakat, S., et al.: Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada. Hematol Oncol 33, 229–238 (2015)PubMedCrossRef Lachaine, J., Mathurin, K., Barakat, S., et al.: Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada. Hematol Oncol 33, 229–238 (2015)PubMedCrossRef
40.
Zurück zum Zitat Lee, E.-K., Revil, C., Ngoh, C.A., et al.: Clinical and cost effectiveness of Bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea. Clin Ther 34, 1408–1419 (2012)PubMedCrossRef Lee, E.-K., Revil, C., Ngoh, C.A., et al.: Clinical and cost effectiveness of Bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea. Clin Ther 34, 1408–1419 (2012)PubMedCrossRef
41.
Zurück zum Zitat Lesnock, J.L., Farris, C., Krivak, T.C., et al.: Consolidation Paclitaxel is more cost-effective than Bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol 122, 473–478 (2011)PubMedPubMedCentralCrossRef Lesnock, J.L., Farris, C., Krivak, T.C., et al.: Consolidation Paclitaxel is more cost-effective than Bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol 122, 473–478 (2011)PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Mihajlović, J., Bax, P., van Breugel, E., et al.: Microcosting study of rituximab subcutaneous injection versus intravenous infusion. Clin Ther 39, 1221-1232.e4 (2017)PubMedCrossRef Mihajlović, J., Bax, P., van Breugel, E., et al.: Microcosting study of rituximab subcutaneous injection versus intravenous infusion. Clin Ther 39, 1221-1232.e4 (2017)PubMedCrossRef
43.
Zurück zum Zitat Nam, J., Milenkovski, R., Yunger, S., et al.: Economic evaluation of Rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. J Med Econ 21, 47–59 (2018)PubMedCrossRef Nam, J., Milenkovski, R., Yunger, S., et al.: Economic evaluation of Rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. J Med Econ 21, 47–59 (2018)PubMedCrossRef
44.
Zurück zum Zitat Pettersson, K., Carlsson, G., Holmberg, C., et al.: Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden: a clinical practice model approach. Acta Oncol 51, 840–848 (2012)PubMedCrossRef Pettersson, K., Carlsson, G., Holmberg, C., et al.: Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden: a clinical practice model approach. Acta Oncol 51, 840–848 (2012)PubMedCrossRef
45.
Zurück zum Zitat Phippen, N.T., Leath, C.A., Havrilesky, L.J., et al.: Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? Gynecol Oncol 136, 43–47 (2015)PubMedCrossRef Phippen, N.T., Leath, C.A., Havrilesky, L.J., et al.: Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? Gynecol Oncol 136, 43–47 (2015)PubMedCrossRef
46.
Zurück zum Zitat Riesco-Martínez, M.C., Berry, S.R., Ko, Y.-J., et al.: Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type kras unresectable metastatic colorectal cancer. J Oncol Pract 12, e710-723 (2016)PubMedCrossRef Riesco-Martínez, M.C., Berry, S.R., Ko, Y.-J., et al.: Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type kras unresectable metastatic colorectal cancer. J Oncol Pract 12, e710-723 (2016)PubMedCrossRef
47.
Zurück zum Zitat Roth, J.A., Carlson, J.J.: Cost-effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine monotherapy in advanced biliary tract cancer. J Gastrointest Cancer 43, 215–223 (2012)PubMedCrossRef Roth, J.A., Carlson, J.J.: Cost-effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine monotherapy in advanced biliary tract cancer. J Gastrointest Cancer 43, 215–223 (2012)PubMedCrossRef
48.
Zurück zum Zitat Schremser, K., Rogowski, W.H., Adler-Reichel, S., et al.: Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics 33, 1215–1228 (2015)PubMedCrossRef Schremser, K., Rogowski, W.H., Adler-Reichel, S., et al.: Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics 33, 1215–1228 (2015)PubMedCrossRef
49.
Zurück zum Zitat van Gils, C.W.M., de Groot, S., Tan, S.S., et al.: Real-world resource use and costs of adjuvant treatment for stage III colon cancer. Eur J Cancer Care (Engl) 24, 321–332 (2015)CrossRef van Gils, C.W.M., de Groot, S., Tan, S.S., et al.: Real-world resource use and costs of adjuvant treatment for stage III colon cancer. Eur J Cancer Care (Engl) 24, 321–332 (2015)CrossRef
50.
Zurück zum Zitat Vergnenegre, A., Corre, R., Berard, H., et al.: Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an Economic, randomized, prospective, multicenter phase III trial comparing Docetaxel and Pemetrexed: the GFPC 05–06 study. J Thorac Oncol 6, 161–168 (2011)PubMedCrossRef Vergnenegre, A., Corre, R., Berard, H., et al.: Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an Economic, randomized, prospective, multicenter phase III trial comparing Docetaxel and Pemetrexed: the GFPC 05–06 study. J Thorac Oncol 6, 161–168 (2011)PubMedCrossRef
51.
Zurück zum Zitat Ward, M.C., Shah, C., Adelstein, D.J., et al.: Cost-effectiveness of Nivolumab for recurrent or metastatic head and neck cancer. Oral Oncol 74, 49–55 (2017)PubMedCrossRef Ward, M.C., Shah, C., Adelstein, D.J., et al.: Cost-effectiveness of Nivolumab for recurrent or metastatic head and neck cancer. Oral Oncol 74, 49–55 (2017)PubMedCrossRef
52.
Zurück zum Zitat Woods, B., Hawkins, N., Dunlop, W., et al.: Bendamustine versus Chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. Value Health 15, 759–770 (2012)PubMedCrossRef Woods, B., Hawkins, N., Dunlop, W., et al.: Bendamustine versus Chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. Value Health 15, 759–770 (2012)PubMedCrossRef
53.
Zurück zum Zitat Zhou, J., Zhao, R., Wen, F., et al.: Cost-effectiveness analysis of Gemcitabine, S-1 and Gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Med Oncol 32, 121 (2015)PubMedCrossRef Zhou, J., Zhao, R., Wen, F., et al.: Cost-effectiveness analysis of Gemcitabine, S-1 and Gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Med Oncol 32, 121 (2015)PubMedCrossRef
54.
Zurück zum Zitat Zhou, K.R., Cheng, A., Ng, W.T., et al.: Cost minimization analysis of Capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong. J Med Econ 20, 541–548 (2017)PubMedCrossRef Zhou, K.R., Cheng, A., Ng, W.T., et al.: Cost minimization analysis of Capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong. J Med Econ 20, 541–548 (2017)PubMedCrossRef
55.
Zurück zum Zitat Zhou, Z.-Y., Mutebi, A., Han, S., et al.: Cost-effectiveness of Ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. J Med Econ 21, 577–586 (2018)PubMedCrossRef Zhou, Z.-Y., Mutebi, A., Han, S., et al.: Cost-effectiveness of Ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. J Med Econ 21, 577–586 (2018)PubMedCrossRef
58.
Zurück zum Zitat Suh, D.-C., Powers, C.A., Barone, J.A., et al.: Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: a microcosting study. Res Social Adm Pharm 6, 246–256 (2010)PubMedPubMedCentralCrossRef Suh, D.-C., Powers, C.A., Barone, J.A., et al.: Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: a microcosting study. Res Social Adm Pharm 6, 246–256 (2010)PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Lavis, J.N., Hammill, A.C.,: Governance arrangements., in Ontario’s health system: key insights for engaged citizens, professionals and policymakers. Hamilton, McMaster Health Forum 45–71 (2016) Lavis, J.N., Hammill, A.C.,: Governance arrangements., in Ontario’s health system: key insights for engaged citizens, professionals and policymakers. Hamilton, McMaster Health Forum 45–71 (2016)
63.
Zurück zum Zitat McGowan, J., Sampson, M., Salzwedel, D.M., Cogo, E., Foerster, V., Lefebvre, C.: PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 75, 40–46 (2016)PubMedCrossRef McGowan, J., Sampson, M., Salzwedel, D.M., Cogo, E., Foerster, V., Lefebvre, C.: PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 75, 40–46 (2016)PubMedCrossRef
Metadaten
Titel
The cost of chemotherapy administration: a systematic review and meta-analysis
verfasst von
Gursharan K. Sohi
Jordan Levy
Victoria Delibasic
Laura E. Davis
Alyson L. Mahar
Elmira Amirazodi
Craig C. Earle
Julie Hallet
Ahmed Hammad
Rajan Shah
Nicole Mittmann
Natalie G. Coburn
Publikationsdatum
09.03.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 4/2021
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-021-01278-0